Loading
Implantable loop recorder / Patient-driven portable ECG monitoring / Heart Failure · Phase 4 Trial
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a prospective, three-arm Phase 4 trial registered at ClinicalTrials.gov comparing implantable loop recorder, patient-driven portable ECG monitoring, and usual care in heart failure patients without known atrial fibrillation, with 18-month follow-up measuring unplanned cardiac care utilization. No results are currently available; the trial has not yet begun recruiting.
Phase 4, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Heart Failure; age from 18 Years. Intervention: Arm 1: Hospital-driven continuous monitoring with an implan…; Arm 2: Patient-driven portable ECG monitoring; Arm 3: Usual Care. Compared with: Usual care from regular doctor without extra devices. n = 258. 1 site: Netherlands.
This is a prospective, three-arm Phase 4 trial registered at ClinicalTrials.gov comparing implantable loop recorder, patient-driven portable ECG monitoring, and usual care in heart failure patients without known atrial fibrillation, with 18-month follow-up measuring unplanned cardiac care utilization. No results are currently available; the trial has not yet begun recruiting.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Once results are available, this trial may inform optimal rhythm monitoring strategy in heart failure patients at risk for incident atrial fibrillation and its consequences. Clinicians should await trial completion and publication before changing practice.
This is a clinical trial registry record with no reported results; the study is not yet recruiting and describes a planned Phase 4 intervention comparing device-based arrhythmia detection to usual care in heart failure.
As stated by the source record.
Quoted from the source exactly as published.
Once results are available, this trial may inform optimal rhythm monitoring strategy in heart failure patients at risk for incident atrial fibrillation and its consequences. Clinicians should await trial completion and publication before changing practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07816458). This is a study registration, not published results. Lead sponsor: Medisch Spectrum Twente. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 258 participants (ESTIMATED). Conditions: Heart Failure. Interventions: DEVICE: Implantable loop recorder; DEVICE: Patient-driven portable ECG monitoring; OTHER: Usual Care. Primary outcome measures: Number of unplanned cardiac care utilization , 18 months. Brief summary: The goal of this clinical trial is to learn if using heart monitoring devices can lower unplanned hospital visits in adults with heart failure (HF). It focuses on adults with heart failure who have no history of an irregular heartbeat called atrial fibrillation (AF). The main questions the trial aims to answer are: Does a heart monitor placed under the skin lower unplanned hospital visits? Does a portable home device lower unplanned hospital visits? Researchers will compare these two groups to a standard care group to see which monitoring approach works best. Participants will: Answer a health survey at the start of the study and after 18 months. Have a small heart monitor placed under their chest skin to watch their heart rhythm, if they are in the first group. Use a handheld device to take weekly heart readings at home, if they are in the second group. Follow standard care from their regular doctor without any extra devices, if they are in the third group.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.